(-)-epigallocatechin-3-gallate inhibition of epstein-barr virus spontaneous lytic infection involves ERK1/2 and PI3-K/Akt signaling in EBV-positive cells

Carcinogenesis

Volumn 34, Issue 3, 2013, Pages 627-637

  Liu, Sufang ^a,b   Li, Hongde ^a   Chen, Lin ^a   Yang, Lifang ^a   Li, Lili ^a   Tao, Yongguan ^a   Li, Wei ^a   Li, Zijian ^a   Liu, Haidan ^a   Tang, Min ^a   Bode, Ann M ^c   Dong, Zigang ^c   Cao, Ya ^a  

^a Central South University   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; EPIGALLOCATECHIN GALLATE; EPSTEIN BARR VIRUS ANTIGEN 1; LATENT MEMBRANE PROTEIN 1; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR BMRF1; TRANSCRIPTION FACTOR BZFL1; UNCLASSIFIED DRUG; VIRUS DNA;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; BURKITT LYMPHOMA; CELL LINE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; ENZYME ACTIVATION; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; GENETIC TRANSCRIPTION; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING; NASOPHARYNX CARCINOMA; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSCRIPTION REGULATION; TUMOR BIOPSY;

ANTIVIRAL AGENTS; CATECHIN; CELL LINE, TUMOR; CELL SURVIVAL; CHROMONES; DNA, VIRAL; ENZYME ACTIVATION; EPSTEIN-BARR VIRUS INFECTIONS; FLAVONOIDS; HERPESVIRUS 4, HUMAN; HUMANS; LYMPHOMA; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASES; MORPHOLINES; NASOPHARYNGEAL NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTO-ONCOGENE PROTEINS C-AKT; VIRAL PROTEINS; VIRUS ACTIVATION;

EID: 84874779840     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgs364     Document Type: Article

References (56)

1. Pathmanathan, R. et al. (1995) Clonal proliferations of cells infected with Epstein-Barr virus in preinvasive lesions related to nasopharyngeal carcinoma. N. Engl. J. Med., 333, 693-698.
2. Young, L.S. et al. (1992) Epstein-Barr virus, lymphomas and Hodgkin's disease. Semin. Cancer Biol., 3, 273-284.
3. Sugawara, Y. et al. (2000) Detection of Epstein-Barr virus DNA in hepatocellular carcinoma tissues from hepatitis C-positive patients. Scand. J. Gastroenterol., 35, 981-984.
4. Kutok, J.L. et al. (2006) Spectrum of Epstein-Barr virus-associated diseases. Annu. Rev. Pathol., 1, 375-404.
5. Rickinson, A.B. et al. (1996) Epstein-Barr virus. In Fields, B.N., Knipe, D.M. and Howley, P.M. (eds) Fields Virology. 3rd edn. Lippincott-Raven Publishers, Philadelphia, PA, pp. 2397-2446.
6. Lei, K.I. et al. (2000) Quantitative analysis of circulating cell-free Epstein-Barr virus (EBV) DNA levels in patients with EBV-associated lymphoid malignancies. Br. J. Haematol., 111, 239-246.
7. Lo, Y.M. (2001) Quantitative analysis of Epstein-Barr virus DNA in plasma and serum: applications to tumor detection and monitoring. Ann. N. Y. Acad. Sci., 945, 68-72.
8. Geser, A. et al. (1982) Final case reporting from the Ugandan prospective study of the relationship between EBV and Burkitt's lymphoma. Int. J. Cancer, 29, 397-400.
9. Mueller, N. et al. (1989) Hodgkin's disease and Epstein-Barr virus. Altered antibody pattern before diagnosis. N. Engl. J. Med., 320, 689-695.
10. Boos, H. et al. (1987) Enhancement of Epstein-Barr virus membrane protein (LMP) expression by serum, TPA, or n-butyrate in latently infected Raji cells. Virology, 159, 161-165.
11. Liu, S.F. et al. (2008) Aspirin induces lytic cytotoxicity in Epstein-Barr virus-positive cells. Eur. J. Pharmacol., 589, 8-13.
12. Israel, B.F. et al. (2003) Virally targeted therapies for EBV-associated malignancies. Oncogene, 22, 5122-5130.
13. Satoh, T. et al. (1999) The interaction of mitogen-activated protein kinases to Epstein-Barr virus activation in Akata cells. Virus Genes, 18, 57-64.
14. Iwakiri, D. et al. (2004) Phosphatidylinositol 3-kinase is a determinant of responsiveness to B cell antigen receptor-mediated Epstein-Barr virus activation. J. Immunol., 172, 1561-1566.
15. Darr, C.D. et al. (2001) Epstein-Barr virus immediate-early protein BRLF1 induces the lytic form of viral replication through a mechanism involving phosphatidylinositol-3 kinase activation. J. Virol., 75, 6135-6142.
16. Ramos, S. (2008) Cancer chemoprevention and chemotherapy: dietary polyphenols and signalling pathways. Mol. Nutr. Food Res., 52, 507-526.
17. Zhao, Y. et al. (2004) Epigallocatechin-3-gallate interferes with EBVencoding AP-1 signal transduction pathway. Zhonghua Zhong Liu Za Zhi, 26, 393-397.
18. Kanwar, J. et al. (2012) Recent advances on tea polyphenols. Front. Biosci. (Elite Ed)., 4, 111-131.
19. Zheng, H. et al. (2007) Role of Epstein-Barr virus encoded latent membrane protein 1 in the carcinogenesis of nasopharyngeal carcinoma. Cell. Mol. Immunol., 4, 185-196.
20. Yang, L. et al. (2009) Effect of DNAzymes targeting Akt1 on cell proliferation and apoptosis in nasopharyngeal carcinoma. Cancer Biol. Ther., 8, 366-371.
21. Ding, L. et al. (2005) Epstein-Barr virus encoded latent membrane protein 1 modulates nuclear translocation of telomerase reverse transcriptase protein by activating nuclear factor-kappaB p65 in human nasopharyngeal carcinoma cells. Int. J. Biochem. Cell Biol., 37, 1881-1889.
22. Liu, S.F. et al. (2008) NF-kappaB inhibitors induce lytic cytotoxicity in Epstein-Barr virus-positive nasopharyngeal carcinoma cells. Cell Biol. Int., 32, 1006-1013.
23. Nagata, Y. et al. (2004) Activation of Epstein-Barr virus by saliva from Sjogren's syndrome patients. Immunology, 111, 223-229.
24. Amon, W. et al. (2004) Lytic cycle gene regulation of Epstein-Barr virus. J. Virol., 78, 13460-13469.
25. Taylor, G.M. et al. (2011) Endoplasmic reticulum stress causes EBV lytic replication. Blood, 118, 5528-5539.
26. Krumbholz, A. et al. (2006) Comparison of a LightCycler-based real-time PCR for quantitation of Epstein-Barr viral load in different clinical specimens with semiquantitative PCR. J. Med. Virol., 78, 598-607.
27. Labrecque, L.G. et al. (1999) Expression of Epstein-Barr virus lytically related genes in African Burkitt's lymphoma: correlation with patient response to therapy. Int. J. Cancer, 81, 6-11.
28. Martel-Renoir, D. et al. (1995) Qualitative analysis of the expression of Epstein-Barr virus lytic genes in nasopharyngeal carcinoma biopsies. J. Gen. Virol., 76 (Pt 6), 1401-1408.
29. Ryan, J.L. et al. (2004) Epstein-Barr virus quantitation by real-time PCR targeting multiple gene segments: a novel approach to screen for the virus in paraffin-embedded tissue and plasma. J. Mol. Diagn., 6, 378-385.
30. Aritaki, K. et al. (2001) A rapid monitoring system of human herpesviruses reactivation by LightCycler in stem cell transplantation. Bone Marrow Transplant., 28, 975-980.
31. Niedobitek, G. et al. (1996) Epstein-Barr virus infection and the pathogenesis of nasopharyngeal carcinoma: viral gene expression, tumour cell phenotype, and the role of the lymphoid stroma. Semin. Cancer Biol., 7, 165-174.
32. Gutierrez, M.I. et al. (1993) Replicative viral DNA in Epstein-Barr virus associated Burkitt's lymphoma biopsies. Leuk. Res., 17, 285-289.
33. Pallesen, G. et al. (1991) Activation of Epstein-Barr virus replication in Hodgkin and Reed-Sternberg cells. Blood, 78, 1162-1165.
34. Chen, C. et al. (2009) Regulation of cellular and viral protein expression by the Epstein-Barr virus transcriptional regulator Zta: implications for therapy of EBV associated tumors. Cancer Biol. Ther., 8, 987-995.
35. Keating, S. et al. (2002) The lytic cycle of Epstein-Barr virus is associated with decreased expression of cell surface major histocompatibility complex class I and class II molecules. J. Virol., 76, 8179-8188.
36. Hahn, A.M. et al. (2005) Interferon regulatory factor 7 is negatively regulated by the Epstein-Barr virus immediate-early gene, BZLF-1. J. Virol., 79, 10040-10052.
37. Adamson, A.L. et al. (2000) Epstein-Barr virus immediate-early proteins BZLF1 and BRLF1 activate the ATF2 transcription factor by increasing the levels of phosphorylated p38 and c-Jun N-terminal kinases. J. Virol., 74, 1224-1233.
38. Cayrol, C. et al. (1996) The Epstein-Barr virus bZIP transcription factor Zta causes G0/G1 cell cycle arrest through induction of cyclin-dependent kinase inhibitors. EMBO J., 15, 2748-2759.
39. Mauser, A. et al. (2002) The Epstein-Barr virus immediate-early protein BZLF1 induces both a G(2) and a mitotic block. J. Virol., 76, 10030-10037.
40. Zhang, Q. et al. (1994) Functional and physical interaction between p53 and BZLF1: implications for Epstein-Barr virus latency. Mol. Cell. Biol., 14, 1929-1938.
41. Adamson, A.L. et al. (1999) The Epstein-Barr virus BZLF1 protein interacts physically and functionally with the histone acetylase CREB-binding protein. J. Virol., 73, 6551-6558.
42. Chien, Y.C. et al. (2001) Serologic markers of Epstein-Barr virus infection and nasopharyngeal carcinoma in Taiwanese men. N. Engl. J. Med., 345, 1877-1882.
43. Cochet, C. et al. (1993) Expression of the Epstein-Barr virus immediate early gene, BZLF1, in nasopharyngeal carcinoma tumor cells. Virology, 197, 358-365.
44. Tsai, S.C. et al. (2009) EBV Zta protein induces the expression of interleukin-13, promoting the proliferation of EBV-infected B cells and lymphoblastoid cell lines. Blood, 114, 109-118.
45. Feng, W.H. et al. (2004) Reactivation of latent Epstein-Barr virus by methotrexate: a potential contributor to methotrexate-associated lymphomas. J. Natl. Cancer Inst., 96, 1691-1702.
46. Kim, J.W. et al. (2010) Chemoprevention of head and neck cancer with green tea polyphenols. Cancer Prev. Res. (Phila)., 3, 900-909.
47. Choi, K.C. et al. (2009) Epigallocatechin-3-gallate, a histone acetyltransferase inhibitor, inhibits EBV-induced B lymphocyte transformation via suppression of RelA acetylation. Cancer Res., 69, 583-592.
48. Taniguchi, S. et al. (2002) Production of bioactive triterpenes by Eriobotrya japonica calli. Phytochemistry, 59, 315-323.
49. Chang, L.K. et al. (2003) Inhibition of Epstein-Barr virus lytic cycle by (-)-epigallocatechin gallate. Biochem. Biophys. Res. Commun., 301, 1062-1068.
50. Yang, C.S. et al. (2011) Cancer prevention by tea: evidence from laboratory studies. Pharmacol Res.
51. Yang, C.S. et al. (2009) Cancer prevention by tea: animal studies, molecular mechanisms and human relevance. Nat. Rev. Cancer, 9, 429-439.
52. Flemington, E. et al. (1990) Identification of phorbol ester response elements in the promoter of Epstein-Barr virus putative lytic switch gene BZLF1. J. Virol., 64, 1217-1226.
53. Barthelman, M. et al. (1998) (-)-Epigallocatechin-3-gallate inhibition of ultraviolet B-induced AP-1 activity. Carcinogenesis, 19, 2201-2204.
54. Petrelli, A. et al. (2008) From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage. Curr. Med. Chem., 15, 422-432.
55. Khan, N. et al. (2008) Multitargeted therapy of cancer by green tea polyphenols. Cancer Lett., 269, 269-280.
56. Bode, A.M. et al. (2009) Epigallocatechin 3-gallate and green tea catechins: united they work, divided they fail. Cancer Prev. Res. (Phila)., 2, 514-517.